313 related articles for article (PubMed ID: 22122798)
1. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
[TBL] [Abstract][Full Text] [Related]
2. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
4. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
5. Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.
Schneiders FL; Huijts CM; Mantici A; Menks MA; Scotet E; Veerhuis R; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2015 May; 158(1):92-9. PubMed ID: 25796193
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells.
Uemura Y; Liu TY; Narita Y; Suzuki M; Nakatsuka R; Araki T; Matsumoto M; Iwai LK; Hirosawa N; Matsuoka Y; Murakami M; Kimura T; Hase M; Kohno H; Sasaki Y; Ichihara Y; Ishihara O; Kikuchi H; Sakamoto Y; Jiao SC; Senju S; Sonoda Y
J Immunol; 2009 Jul; 183(1):201-8. PubMed ID: 19542431
[TBL] [Abstract][Full Text] [Related]
7. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
9. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
Macho Fernandez E; Chang J; Fontaine J; Bialecki E; Rodriguez F; Werkmeister E; Krieger V; Ehret C; Heurtault B; Fournel S; Frisch B; Betbeder D; Faveeuw C; Trottein F
Int J Pharm; 2012 Feb; 423(1):45-54. PubMed ID: 21575695
[TBL] [Abstract][Full Text] [Related]
10. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
[TBL] [Abstract][Full Text] [Related]
11. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
12. Role of marginal zone B lymphocytes in invariant NKT cell activation.
Bialecki E; Paget C; Fontaine J; Capron M; Trottein F; Faveeuw C
J Immunol; 2009 May; 182(10):6105-13. PubMed ID: 19414762
[TBL] [Abstract][Full Text] [Related]
13. Costimulatory activation of murine invariant natural killer T cells by toll-like receptor agonists.
Kulkarni RR; Villanueva AI; Elawadli I; Jayanth P; Read LR; Haeryfar SM; Sharif S
Cell Immunol; 2012; 277(1-2):33-43. PubMed ID: 22795895
[TBL] [Abstract][Full Text] [Related]
14. Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis.
Bharhani MS; Chiu B; Na KS; Inman RD
Int Immunol; 2009 Jul; 21(7):859-70. PubMed ID: 19477915
[TBL] [Abstract][Full Text] [Related]
15. Altered invariant natural killer T cell subsets and its functions in patients with oral squamous cell carcinoma.
Singh AK; Shukla NK; Das SN
Scand J Immunol; 2013 Nov; 78(5):468-77. PubMed ID: 23980793
[TBL] [Abstract][Full Text] [Related]
16. CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis.
Schneiders FL; Prodöhl J; Ruben JM; O'Toole T; Scheper RJ; Bonneville M; Scotet E; Verheul HM; de Gruijl TD; van der Vliet HJ
Cancer Immunol Res; 2014 Aug; 2(8):732-40. PubMed ID: 24934445
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
[TBL] [Abstract][Full Text] [Related]
18. In vitro expanded human invariant natural killer T-cells promote functional activity of natural killer cells.
Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
Clin Immunol; 2008 Oct; 129(1):145-54. PubMed ID: 18707922
[TBL] [Abstract][Full Text] [Related]
19. [Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes].
Catros V; Toutirais O; Bouet F; Cabillic F; Desille M; Fournié JJ
Med Sci (Paris); 2010 Feb; 26(2):185-91. PubMed ID: 20188051
[TBL] [Abstract][Full Text] [Related]
20. Production of both IL-27 and IFN-gamma after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model.
Fujita H; Teng A; Nozawa R; Takamoto-Matsui Y; Katagiri-Matsumura H; Ikezawa Z; Ishii Y
J Immunol; 2009 Jul; 183(1):254-60. PubMed ID: 19542437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
